# GR1803 Injection in Patients With Relapsed/Refractory Multiple Myeloma

Source: https://onco.cc/trials/nct06566547/  
OnCo record `nct06566547` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of GR1803 in multiple myeloma, run by Genrix (Shanghai) Biopharmaceutical Co., Ltd., active and no longer recruiting.

## Summary

GR1803 Injection in Patients With Relapsed/Refractory Multiple Myeloma is a phase 2 interventional study registered as NCT06566547 by Genrix (Shanghai) Biopharmaceutical Co., Ltd., with 116 participants planned, started 2024-08-26 and due to reach its primary completion in 2027-05-12. Interventions recorded: GR1803 injection. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06566547
- Phase: 2
- Setting: Single-Arm, Open, Multi-Center Phase II Clinical Trial of the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of GR1803 Injection in Patients With Relapsed/Refractory Multiple Myeloma
- Sponsor: Genrix (Shanghai) Biopharmaceutical Co., Ltd.
- Enrolled: 116

## Sources

- ClinicalTrials.gov NCT06566547: https://clinicaltrials.gov/study/NCT06566547

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- drugs: [GR1803](https://onco.cc/drugs/gr1803/)

---
JSON: https://onco.cc/api/v1/entities/nct06566547.json